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Abstract
Family history of colorectal cancer (CRC) is a known risk factor for CRC, and encompasses both 
genetic and shared environmental risk. We conducted a systematic review to estimate the impact of 
family history on the natural history of CRC and adherence to screening. We found high 
heterogeneity in family history definitions, the most common definition being one or more first-
degree relatives. The prevalence of family history may be lower than commonly cited 10%, and 
confirms evidence for increasing levels of risk associated with increasing family history burden. 
There is evidence for higher prevalence of adenomas and of multiple adenomas in people with 
family history of CRC, but no evidence for differential adenoma location or adenoma progression 
by family history. Limited data on the natural history of CRC by family history suggests a 
differential age or stage at cancer diagnosis and mixed evidence on tumor location. Adherence to 
recommended colonoscopy screening was higher in people with family history of CRC. 
Stratification based on polygenic and/or multifactorial risk assessment may mature to the point of 
displacing family history-based approaches, but for the foreseeable future family history may 
remain a valuable clinical tool for identifying individuals at increased risk of CRC.
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 INTRODUCTION
Colorectal cancer (CRC) ranks third in cancer incidence and death in the United States. 
About 4% of CRCs occur in those younger than 50 years of age.1 Hereditary conditions such 
as familial adenomatous polyposis (FAP) and Lynch syndrome confer an extremely high 
lifetime risk of CRC but account for a minority of all CRCs. A much larger proportion of US 
adults have moderately-elevated risk of CRC due to a family history of CRC, likely due to a 
combination of shared polygenic and shared environmental risk.2,3,4
Early detection of CRC through screening with established modalities beginning at age 50 
reduces CRC morbidity and mortality, but adherence to CRC screening remains below the 
CDC’s goal of 80%.5,6 Optimal screening for people with established family history of CRC 
is not as well defined, and screening recommendations vary and focus on earlier initiation of 
screening, frequency of screening, or early screening in people in racial/ethnic groups.7–12 If 
optimal screening strategies could be determined based on evidence-based risk, and 
adherence to screening could be improved, there is significant potential for further public 
health impact. Statistical modeling can give valuable information on how different screening 
practices might impact population outcomes, but population-based, high quality 
epidemiologic data is needed to inform such models.
We conducted a systematic review to identify evidence for the impact of family history of 
CRC on the risk and natural history of colorectal cancer, and on screening adherence. The 
review was commissioned by the Evaluation of Genomic Applications in Practice and 
Prevention (EGAPP) Working Group and designed to inform a decision-analytic model of 
optimal screening strategies conducted by the National Cancer Institute Cancer Intervention 
and Surveillance Modeling Network (CISNET) consortium microsimulation modeling 
group.13 Due to the lack of studies at the time of the review suggesting clinical utility of 
polygenic models of moderate-penetrance gene variants for assessing colorectal cancer risk, 
we focused the review on the evidence for family history.
We systematically reviewed four areas: Prevalence: What is the prevalence of a positive 
family history of CRC or adenoma in the population? Does prevalence vary by age, sex, and 
race/ethnicity of the person at risk for family history? Risk: What are the absolute and 
relative risks for CRC or adenoma associated with positive family history of CRC? Natural 
history: How does a positive family history of CRC impact the natural history of CRC and 
adenomas? Adherence: How does family history of CRC impact adherence to colonoscopy?
 MATERIALS AND METHODS
 Search strategy and study selection
Systematic literature searches were performed through February 20, 2013 in Medline, 
PubMed, and Centre for Reviews and Dissemination. Searches were broadly scoped, using 
Henrikson et al. Page 2













terms for CRC, family history, natural history, and screening adherence.(supplemental 
material) Two investigators independently reviewed identified abstracts and articles against a 
priori specified inclusion criteria. Disagreements were resolved through consensus or input 
of a third reviewer. Detail of search strategies, study selection, analysis and results are 
available in the supplemental materials.
Inclusion criteria for all questions included age of the person at risk ≥18 and study reported 
in English language. Exclusion criteria for all questions included illness-associated CRC 
(e.g. Crohn disease), inherited CRC syndromes, and studies with unmeasured or poorly 
defined family history criteria. Only studies reporting family history in terms of both number 
and degree of relatedness for affected family members were included.
For risk, prevalence, and adherence, we included only population-based estimates. Case 
control studies were excluded to minimize bias by enrichment with people with family 
history of CRC. For natural history we included only studies that would allow assessment by 
family history of age of onset of adenoma or CRC, number of adenomas or tumors, 
advanced adenoma, and adenoma/tumor location. Case-only and case-control studies were 
permitted for this question.
We reviewed all included studies for the independence of their study populations and years 
of data collection. For studies from the same data source we included papers that best fit the 
relevance to the study questions.
Due to the large number of studies and heterogeneity of outcomes and family history 
definitions, we further refined our inclusion criteria using a best evidence approach, a staged 
method for prioritizing evidence from all potentially relevant to a set best suited to 
answering a question. Such approaches can be appropriate for large, heterogeneous 
literatures to enhance applicability of the evidence.14 For risk and prevalence we defined our 
best evidence set as population-based studies with a minimum sample size of 30,000, a 
number chosen by team consensus, and excluding screening studies as these may over-
represent people with family history. For natural history we limited to studies where 
colonoscopy was conducted in a minimum sample size of 500 people with CRC or adenoma. 
For adherence, we identified an existing comprehensive review that contained data highly 
relevant to our study question15 and included this as a source of primary evidence,16 
supplemented by subsequent US population-based studies.
 Data abstraction, synthesis, and quality assessment
Histological characteristics of tumors and adenomas of interest to this review were informed 
by the World Health Organization histology resource17 in consultation with clinical experts 
(supplemental material). We abstracted estimates of prevalence or relative risk, with 
confidence intervals where provided. For the adherence question we limited data abstraction 
to adults age 50+ to reflect current screening recommendations. We did not conduct meta-
analyses due the heterogeneity of outcomes measures and family history definitions. We 
critically appraised the best evidence set for threats to internal validity from selection; 
attrition, detection, and reporting bias, adapting criteria from previously published 
approaches.15,18
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From 3271 abstracts, 437 articles met inclusion criteria. Of those, 224 were excluded after 
review of the full text for risk, prevalence, and natural history; 96 were excluded for 
adherence. After applying best evidence criteria our dataset included 30 unique articles: 8 
addressed prevalence, 9 addressed risk, 9 addressed natural history, and 11 adherence 
(Figure 1).
 Prevalence
Summary: The prevalence of having at least one first degree relative (FDR) was estimated 
between 3.1% and 10%. The prevalence of having at least two FDRs was much lower 
(0.3% to 0.34%). Having a FDR with an early age at diagnosis (before age 45 or 50 years) 
was uncommon, around 0.3%, compared with having a FDR with a later diagnosis (above 
age 60 or 65 years), which was over 3%. Few data were available on racial and ethnic-
specific prevalence of family history.
 Study details—Eight studies met our best evidence criteria:2,19–25 six were from the 
US, one from the UK23 and one from Japan.21 All had approximately equal representation 
of males and females except two studies that included women only24,25 The average age in 
the study populations was between 50 and 60 years except one,20 which had average age of 
39.3 years. All studies but one19 ascertained family history information from unverified self-
report (Table 1).
The most common definition of family history was one or more first degree relatives (1+ 
FDR). Five studies estimated the prevalence of having 1+ FDR, with estimates ranging 
between 3.1% and 10%.2,19,23–25 The only study with objective measures of both family 
history and CRC diagnosis estimated positive family history prevalence of 4.1%.19 The 
lowest estimate was from a study that evaluated only mothers and daughters and likely 
underestimates the prevalence of a positive family history. Two studies provided estimates 
for the prevalence of having exactly one FDR, which were 3.9% and 9.4%.19,22 One study 
provided an estimate for having at least one affected parent (1.7%).21 The prevalence of 
having at least two affected FDRs was 0.3% to 0.34%.19,23
Scheuner et al20 estimated the prevalence of multiple family history configurations grouped 
together in risk groups. The “moderate risk” group, defined as either 1 FDR with late onset 
cancer or 2 SDRs from the same lineage with late onset cancer or one SDR with early onset 
cancer and other SDRs with associated cancers had a prevalence of 4.2%. Two studies 
considered the relative’s age at diagnosis as part of the definition of family history.19,23 As 
expected, having a FDR diagnosed below age 45 (prevalence 0.36%23) or 50 (prevalence 
0.27%19) was much less common than having a FDR diagnosed above age 60 (3.4%19 or 65 
(4.1%23).
Two studies considered the effect of demographic characteristics. Both found higher 
prevalence of family history in females compared to males (6.1% of men and 7.4% of 
women with at least 1 FDR23 and 4.5% of men compared to 6.2% of women in the author-
defined “strong” or “moderate” risk groups.20 “Moderate” or “strong” family history was 
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also higher among whites than other racial or ethnic groups in the same study (7.3% white, 
2.5% Latino, 4.1% Asian, 6.1% AA, 4.4% other)20.
 Risk
Summary: The relative risk of developing CRC varied from 0.89 (for people with no 
family history) to nearly a 20-fold risk (for people with likely inherited syndromes), with 
risk levels in between, with increasing family history burden. Risk of CRC was higher 
when the relative was diagnosed at an earlier age. CRC risk also depended on the age of 
the person at risk: people with positive family history in their 30s or 40s demonstrated a 
higher relative risk compared to their age-matched peers than people with the same 
positive family history at an older age.
Nine studies of unique populations ranging in size from 30,353 to 7 million individuals were 
included.2,19–21,23–27 Five studies were conducted in the US,2,19,20,24,25 four others were 
from Britain,23 Sweden,27 Japan,21 and China.26 Most studies considered the risk of 
developing colorectal cancer in those with family histories of CRC compared to those with 
no family history. One very large study considered standardized incidence ratios for 
colorectal cancer people with family history compared with the general population.19 
Summarized results for risk are shown in Table 2; detailed tables are in the supplementary 
materials.
The Utah Population Database (UPDB) is a state-wide population-based resource of 
genealogies of the original Utah pioneers and their modern-day descendants. This analysis 
used Utah Cancer Registry data (from 1952) linked to the UPDB in a subset of 2.3 million 
persons who were part of 3 generations of Utah genealogy data and descendants of original 
Utah pioneers.
Analyses from the UPDB using detailed family pedigrees found distributions of 
standardized incidence ratios for CRC from 0.89 (95% CI 0.87–0.91) for those with no first 
degree relatives with CRC to 19.86 (95% CI 9.29–43.24) for those with five or more first 
degree relatives, who likely have inherited syndromes.19 Significant differences in CRC 
incidence were present between those with confirmed negative family history (0.89), one 
first degree relative date of diagnosis unknown or after age 60 (1.91–1.99), one first degree 
relative diagnosed before age 60 (2.69), and 3 or 4 first degree relatives (4.41). The Nurses’ 
Health Study (NHS) found increased risk for CRC from 1+FDR to 2+ FDR.2 In the UPDB 
having a FDR diagnosed before age 60 years increased personal CRC risk. Other US data 
were consistent with an earlier diagnosis of CRC in a first degree relative conferring higher 
personal CRC risk, but were not consistently defined (i.e., used different ages to stratify 
earlier diagnosis) to contribute to precise risk estimates by age of relative’s CRC 
diagnosis.2,24
In the Swedish Family Cancer database, data from 7 million people representing over 2 
million families was linked with the Swedish Cancer registry.27 The individuals represented 
offspring born after 1934, who had at least two siblings, and their parents. Having a parent 
with CRC was associated with a doubling of risk, and a tripling of risk if the parent was 
diagnosed younger than age 60.27 One Chinese study looked at risk associated with affected 
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siblings versus parents and did not suggest greater impact of sibling CRC over parental 
CRC.26
Three studies provided relative risks stratified by the age of the person at risk. In the 
Swedish database, the presence of a parental history of CRC more than quadrupled CRC risk 
in adults aged 30–39 years, compared to others the same age with no family history.27 
Within each age decile of the person at risk, parental cancer history was associated with 
increased relative risks compared to people without an affected parent of the same age. 
Relative risks remained elevated until at least age 70. Data from the Health Professionals 
Followup Study and Nurses’ Health Study populations was generally consistent.2 British 
data on prevalent, rather than incident cancer, suggest decreasing risk with increasing age of 
the person at risk but confidence intervals were wide; also this study population did not 
include people under 50 where the risk may be most exaggerated..23 Overall, the 
preponderance of data suggests that history of one or more FDR with CRC is associated 
with a smaller and diminishing incremental increase in relative risk in those aged 50 years 
and older, as the prevalence of family history in the population increases. Thus, the relative 
impact of family history on preventable cancers in those under ages 50–55 years will be 
much greater than in older adults (see supplemental tables).
 Critical appraisal concerns: risk and prevalence studies—All but one22 study 
controlled for age of the person at risk, and five controlled for the sex of the person at 
risk.2,19,22,23,25 Only one study21 adjusted for family size, and no studies reported if or how 
relatedness of the study participants was addressed. Only two studies used verified family 
histories, both with registry-based outcomes.19,27 All the others used self-report. Studies of 
non-US populations may have limited generalizability to US populations.
 Natural history
Adenoma summary: There are very few data with which to make a strong conclusion 
about adenoma and family history. Data from two studies suggest a higher prevalence of 
adenomas in people with a positive family history of CRC compared with people with no 
family history. There was a higher prevalence of two or more adenomas in people with a 
positive family history of CRC compared with people with no family history. No evidence 
suggested differential adenoma location by family history status. There is no evidence to 
suggest a differential prevalence of advanced adenoma in people with a family history of 
CRC.
Cancer summary: Very limited data were available on family history, natural history and 
CRC. There was no evidence for difference in age at CRC diagnosis or stage at diagnosis 
by family history status. There was mixed evidence on tumor location depending on family 
history status: Some evidence suggested that those with a positive family history are more 
likely to have distal tumors, whereas others reported no difference.
We identified 9 unique studies: 3 with relevant adenoma outcomes28–30, and six with 
relevant CRC outcomes.31–36
Henrikson et al. Page 6













 Adenoma study details—We identified three studies on a total of 35,590 people with 
family history-specific data on adenoma prevalence (two studies), advanced adenomas (three 
studies), multiple adenomas (three studies), or adenoma location (one study).28–30 In a study 
of 27,650 men enrolled in the Health Professionals Follow-up Study (HPFS) from 1986–
2004,28 adenoma prevalence was increased in people with exactly one 1 FDR (15.4%) or 2+ 
FDRs (19.1%) compared to people with no family history (10.0%) (Table 3). Adenomas 
were more common in people with family history at all age groups particularly at younger 
ages based on slopes of weighted regression lines;, raw data not provided). A German 
population-based cross-sectional study of colonoscopies of 3,320 people at average risk 
found a similar trend, finding higher adenoma prevalence than HPFS for those with no 
affected FDRs (30% vs 10%) and 1+ FDR (40% vs 15%).29
The HPFS study suggested that the odds of advanced adenoma associated with family 
history was similar to that of any adenoma.28 In the German study advanced adenoma was 
more prevalent in men than women regardless of family history (Table 3).29 The German 
study included CRC in an “advanced neoplasia” category (3.9% of total neoplasia, data not 
shown).
The HPFS analysis provided data on 2+ adenomas by family history and was limited to 
distal location.28 It suggested an increasing prevalence of 2+ adenomas with increasing 
family history. The adjusted odds of multiple adenomas remained when compared to either 
single adenomas or no adenomas.
A screening study of Veterans Affairs patients (n=3121, 96.8% male; age 50–75), did not 
describe the family history of the entire study population but reported a higher rate of family 
history (1+ parent or sibling) in people with two or more adenomas (19.3%) compared to 
people with one adenoma (12.9%) or no polyps (12.2%) (OR 1.73, 95% CI 1.32–2.26); 
similarly for advanced adenoma (18.4% with advanced adenoma vs 15.8% with any 
adenoma (OR for advanced adenoma vs no polyp group: 1.62 (95% CI 1.16–2.26); OR for 
any adenoma vs no polyp group: 1.36 (1.09–1.70;).30 Only the German study reported 
adenoma location by family history (proximal/distal and colon/rectum) and found no 
significant difference in the distribution of location according to family history.28
 Critical appraisal: adenoma studies—The study populations of two of the three 
studies were almost exclusively male, limiting their generalizability to women28,30 but 
otherwise included populations of screening-relevant age. Three studies assessed natural 
history outcomes via study colonoscopy;29,30 one used self-report but verified positive 
findings with medical records.28 All studies included adequate followup time to detect the 
findings of interest, either by cross sectional analysis of colonoscopy findings or longitudinal 
design. Three studies relied on self-report of family history;28,30 one with verification of 
self-report via medical records or death certificates.29
 Cancer studies—Four studies on 4,537 people reported data on age at diagnosis by 
family history of CRC.31,32,34,35 A study of 3383 surgical CRC patients in Taiwan found no 
difference in age at detection in those with 0 or 1 FDR, but a lower age at detection for those 
with 2+ FDRs. However, this group included Lynch patients so may reflect differential 
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surveillance. An analysis of 1,001 women enrolled in the Nurses’ Health Study found no 
difference in age at diagnosis according to family history.34
Two studies reported age of diagnosis by family history. A randomized trial for adjuvant 
therapy for stage III colon cancer in people within 56 days of surgery for a primary tumor 
did not find any baseline difference in age at trial enrollment by family history.35 A US 
registry-based analysis of incident cancer between 1994–1996 did not find any difference 
between age at diagnosis for colon cancer by family history, but younger age at diagnosis for 
rectal cancer in people with no family history.31
Four studies reported data by family history on location of CRC at diagnosis. Registry-based 
studies in Sweden and Japan suggested the majority of cancers in people with a family 
history were distally located.33,36 However, two other studies found a more even distribution 
of distally and proximally located cancers.32,34 In three studies providing data on stage at 
diagnosis by family history, there was no evidence of differential distributions of stage in 
people with a family history of CRC compared to those without.31–33
 Critical appraisal concerns: cancer studies—The natural history of CRC is 
difficult to assess because of the known effectiveness of treatment for detected CRC. Age at 
diagnosis was obtained at study enrollment for two studies32,35 and from registry data for 
one;33,37 one study collected self-report data but verified positive results with medical 
records.34 Family history was assessed by interview,31,32 self-report,34,35 or from registry 
records.33,37 No studies reported measures of relatedness or family size.
 Adherence
Summary: Individuals with a positive family history are 1.4 to 3.3 times more likely to be 
adherent to colorectal cancer screening recommendations than individuals with no family 
history. One study, which objectively measured both family history and screening behavior 
suggested a 7%–8% absolute increase in screening adherence in people with positive 
family history.
 Study details—We assessed three studies published since 2009, plus 8 studies from the 
systematic review used as primary evidence15 for a total of 11 studies. Ten were cross-
sectional studies, together representing 9 independent samples and 129,942 people age 50 
years and older (Table 4). All studies but one38 used a relatively non-specific family history 
definition of 1+ FDR with CRC.38 Only the three newer studies included age of affected 
relative’s diagnosis (<age 50) as a separate analysis.38–40 Three analyzed colonoscopy 
adherence alone;39–41 all others considered adherence to recommended CRC screening 
modalities (colonoscopy, sigmoidoscopy, and/or FOBT). Eight studies published adherence 
rates;38–40,42–46 three published relative risks of adherence for those with family history 
compared with no family history.
An analysis of the 2005 California Health Interview Survey included 10,310 adults aged 50–
64, 7.5% of whom had a self-reported family history of CRC,38 those with a family history 
of 1+ FDR or 2+ SDRs were more than twice as likely to be adherent with CRC screening 
recommendations (OR 2.77, 95% CI 2.20–3.49). Absolute adherence was increased by more 
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than 25%. In an analysis of 2008 Oregon Behavioral Risk Factor Surveillance System data, 
adherence was more than twice as likely in those with 1+FDR, regardless of screening 
criteria used, although estimates were less precise likely due to sample size.40 Absolute 
adherence was at least 20% greater in those with a self-reported family history, and 
somewhat higher when not requiring colonoscopy.
In an analysis of the Utah Population Database 2004–2009,39 cancer history was confirmed 
via the Utah Cancer Registry and family relationships were established using comprehensive 
statewide genealogy data. Adherence to colonoscopy in the previous ten years was increased 
in those with 1+FDR, but with somewhat attenuated relative (OR 1.40, 95% CI 1.33 to 1.47) 
and absolute effects (7% higher adherence) compared to the two other studies. This study is 
the only one to use systematic, objective approaches to assess family history and 
colonoscopy rather than self-reported data, which could explain the more modest effect size.
The eight older studies consistently found around a doubling of the odds of reporting 
compliance with recommended CRC screening, regardless of the definitions of 
recommended CRC screening or population, corresponding to adherence rates of 26%–50% 
for people with no family history compared with 44%–68% for people with 1+ FDR. 
Precision varied with sample size, and data to evaluate screening adherence with 
colonoscopy versus other modalities were limited and mixed (supplemental materials).
 Critical appraisal concerns: adherence studies—Ten of eleven studies gathered 
both exposure and outcome data via self-report and only one used registries and medical 
records to verify family history and screening use.39 Survey-based studies found varying 
response rates, from quite low response rate of 29%38 to a high of 79%.44 Four studies did 
not report the response rate so response bias could not be assessed.40,45,47,48
 DISCUSSION
We conducted a systematic review to identify the most current, highest quality evidence of 
the prevalence of family history of colorectal cancer in the US population, as well as its 
influence on CRC risk, natural history, and screening adherence. These data provide 
important insights to clinicians and researchers, and support further modeling of effective 
and efficient evidence-based screening recommendations for those at more precisely 
increased risk of CRC due to more completely defined family histories. Our study suggests 
that objective measures of prevalence of family history may be lower than commonly cited; 
that the increased risk associated with family history is significant and may be associated 
with adenoma number rather than by faster adenoma progression. People with family history 
were more likely to adhere to screening than those without. Taken together, these data 
reinforce the need for optimal screening strategies for people with family history of 
colorectal cancer.
 Prevalence
Our findings suggest that the prevalence of family history may be lower than the commonly 
discussed estimate of 10%, which is likely based on self-reported data. This may reflect our 
emphasis on studies that focused on population samples rather than screening studies, to 
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minimize bias due to selective volunteering of patients and families with positive family 
histories. Though the prevalence of second degree relatives was higher than that of first 
degree relatives,19 family history considering various family patterns involving second or 
third degree relatives was never associated with more than a doubling of CRC risk. This 
suggests that for clinical purposes, determining the history of cancer in all first degree 
relatives may be both sufficient and the most feasible. Earlier age of FDR diagnosis with 
CRC was relatively consistently associated with further increased risk, but current data made 
the degree of additional risk difficult to quantify. Only one study reported prevalence of 
family history by race but suggested prevalence at odds with actual increased CRC 
prevalence in African Americans.20 If these data are correct, family history may be 
underreported, less-well known, or not a primary influence in the excess CRC burden in 
African Americans. One study suggested higher prevalence of family history in females, 
suggesting gender differences in reporting consistent with other studies.18,49
 Risk
Our review of population-based risk estimates suggested a range of risk from 0.89 (for 
individuals with no family history) to nearly a 20-fold risk for individuals with likely 
inherited syndromes, with risk levels in-between depending on the family history 
configuration. This is consistent with those in other reviews50,51 suggesting increasing risk 
of CRC with increasing burden of family history. Our review has the added benefit of using 
only population-based study populations and adds results from a high quality study using a 
comprehensive US-based population.19 This study used the entire population as the 
comparator in risk estimates, allowing subpopulation estimates that ranged from a modestly 
reduced risk to an exaggerated risk for the very few with five or more first degree relatives. 
Importantly, relative risks for CRC varied between 1.9 and 4.4 in those with at least one 
FDR, depending on the number of relatives and age of diagnosis. It also included relative 
risk estimates stratified by age of the person at risk. This study represents a population with 
potentially lower behavioral risk factors, such as smoking and alcohol use, than the general 
population. Concern is frequently raised about how genetically representative this population 
is, but the UPDB is genetically representative of US Caucasian and northern European 
populations with a low level of inbreeding.52–54 This study is of high quality and its methods 
should be replicated wherever possible using other data sources.
Evidence for adenoma and/or CRC risk in people with a family history of adenoma (rather 
than CRC) is limited; no studies of this type met our best evidence criteria. One review 
found only two studies, both with methodologic flaws.55 A paper published after our search 
ended suggests increased risk of both CRC and adenoma in people with family history of 
adenoma.56
 Natural history
Our best evidence suggests a higher prevalence of adenomas in people with family history of 
CRC in men, consistent with previous work57 but does not suggest that adenoma progression 
(measured by advanced adenoma) is accelerated in people with family history. Small studies 
have suggested that adenoma growth may be accelerated in people with a family history of 
CRC.58,59 Future, larger studies could provide additional insight on the impact of family 
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history on adenoma progression. Evolving temporal trends in adenoma classification, such 
as the sessile serrated pathway, made it challenging to pool data from multiple studies.
Two studies suggested a trend toward increased multiple adenomas in people with a family 
history of CRC. Our best evidence did not suggest an association between adenoma location 
and family history. For colorectal cancer, the data were even more limited, but suggested no 
difference in the age or stage at diagnosis by family history status. There was very limited, 
conflicting evidence on tumor location and family history. Very limited data suggest that 
CRC progression in people with family history of CRC is similar to that in the general 
population.
 Adherence
Our review confirms the findings of a previous review suggesting a clear association 
between family history of CRC and adherence with both colonoscopy and other CRC 
screening modalities.15 Increased adherence likely reflects both organizational (physician 
recommendation, access) and patient-level factors such as risk perception, but it is worth 
noting that adherence remains low in all groups. Only one study provided data using 
objectively measured family history and screening; these data may provide the best 
estimates for adherence for those with a positive family history but are limited to a single 
geographic location with a somewhat different social environment.
Our best evidence approach allowed us to summarize an extensive, heterogeneous body of 
research, but may have resulted in our excluding some relevant data. To our knowledge this 
is the first review to limit estimates of prevalence of family history and CRC risk to 
population-based studies, which may be the least biased for informing modeling of 
population-based screening.
We were also limited by the heterogeneous nature of family history reporting in the 
literature. There is often analytical rationale for collapsing family history strata to increase 
sample size, but this makes it difficult to pool data across studies. We excluded 41 studies 
based on the lack of a basic definition that included number and degree of relatives affected 
and a further 43 for not providing data stratified by family history. In the remaining studies, 
more than half used our minimum family history definition of “at least one FDR.” Few 
studies reported age at diagnosis of the affected relative, verified the accuracy of self-
reported data or used objective measures, or assessed or adjusted for family size.
We recommend that future research define family history as, at minimum, the number and 
degree of affected relatives, and that raw data be reported to maximize potential for 
aggregating study data. Family history studies should also report how history was assessed, 
whether and how it was verified, and family size. Measures of how often family history 
changes in ways that materially impact an individual’s CRC risk as they age would help 
reduce the uncertainty associated with family history at younger ages and the frequency with 
which family history for CRC should be updated. High-quality studies of family history and 
CRC in populations of non-European ancestry are also needed.
Henrikson et al. Page 11













Family history is an imperfect and dynamic measure. As family sizes decrease over time, 
fewer relatives are available to define risk. Also, as endoscopic screening with curative 
intervention increases, family history can be hidden in families if affected persons are more 
likely to communicate a diagnosis of advanced cancer to their relatives than a polyp 
removed during endoscopy. However, family history of CRC remains a clinically meaningful 
way to identify individuals at increased risk of CRC, and may be the most feasible approach 
at present, given that multifactorial risk assessment tools are not yet validated for clinical 
practice60–65 and the utility of genetic risk stratification is still being investigated.66–68 In 
future, risk based on polygenic and/or multifactorial risk assessment may augment family 
history-based approaches.69 Family history collection and reporting should continue in ways 
that are conducive to knowledge development.
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